Brokerages predict that Petmed Express Inc (NASDAQ:PETS) will report earnings of $0.43 per share for the current quarter, Zacks reports. Three analysts have made estimates for Petmed Express’ earnings. Petmed Express reported earnings per share of $0.37 during the same quarter last year, which suggests a positive year over year growth rate of 16.2%. The company is expected to issue its next earnings report on Monday, May 14th.
On average, analysts expect that Petmed Express will report full-year earnings of $1.76 per share for the current financial year. For the next fiscal year, analysts forecast that the firm will report earnings of $2.14 per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Petmed Express.
Petmed Express (NASDAQ:PETS) last announced its earnings results on Monday, January 22nd. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.11. The business had revenue of $60.10 million for the quarter, compared to analyst estimates of $56.76 million. Petmed Express had a return on equity of 34.04% and a net margin of 12.84%. The company’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.24 EPS.
PETS has been the topic of a number of research analyst reports. BidaskClub upgraded Petmed Express from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 9th. Northcoast Research set a $58.00 target price on Petmed Express and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. Noble Financial restated a “hold” rating on shares of Petmed Express in a research note on Friday, October 27th. Finally, ValuEngine upgraded Petmed Express from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $42.80.
Shares of Petmed Express (NASDAQ:PETS) traded down $1.64 during midday trading on Thursday, reaching $45.23. The company’s stock had a trading volume of 748,540 shares, compared to its average volume of 845,724. The company has a market cap of $931.79, a price-to-earnings ratio of 25.13, a P/E/G ratio of 2.69 and a beta of 0.95. Petmed Express has a fifty-two week low of $19.21 and a fifty-two week high of $57.80.
The company also recently disclosed a quarterly dividend, which was paid on Friday, February 16th. Stockholders of record on Monday, February 5th were issued a $0.25 dividend. This is a boost from Petmed Express’s previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.21%. The ex-dividend date was Friday, February 2nd. Petmed Express’s dividend payout ratio is presently 55.56%.
In other news, Director Gian Fulgoni sold 20,000 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $44.38, for a total value of $887,600.00. Following the completion of the transaction, the director now directly owns 55,900 shares in the company, valued at approximately $2,480,842. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronald J. Korn sold 5,000 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $48.38, for a total value of $241,900.00. Following the completion of the transaction, the director now owns 68,833 shares of the company’s stock, valued at $3,330,140.54. The disclosure for this sale can be found here. Insiders sold a total of 65,000 shares of company stock valued at $3,229,500 over the last quarter. Company insiders own 4.00% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Elkfork Partners LLC purchased a new position in shares of Petmed Express in the 4th quarter worth about $100,000. Sei Investments Co. boosted its holdings in shares of Petmed Express by 50,142.9% in the 3rd quarter. Sei Investments Co. now owns 3,517 shares of the company’s stock worth $117,000 after purchasing an additional 3,510 shares in the last quarter. LS Investment Advisors LLC boosted its holdings in shares of Petmed Express by 283.5% in the 4th quarter. LS Investment Advisors LLC now owns 2,861 shares of the company’s stock worth $130,000 after purchasing an additional 2,115 shares in the last quarter. Sterling Investment Advisors Ltd. boosted its holdings in shares of Petmed Express by 118.5% in the 4th quarter. Sterling Investment Advisors Ltd. now owns 2,950 shares of the company’s stock worth $134,000 after purchasing an additional 1,600 shares in the last quarter. Finally, Thompson Siegel & Walmsley LLC purchased a new stake in Petmed Express during the 3rd quarter valued at about $149,000. Hedge funds and other institutional investors own 92.01% of the company’s stock.
WARNING: This report was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/22/zacks-analysts-anticipate-petmed-express-inc-pets-will-announce-earnings-of-0-43-per-share.html.
About Petmed Express
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Get a free copy of the Zacks research report on Petmed Express (PETS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.